NDC 25021-305-66 Chlorothiazide Sodium

Chlorothiazide Sodium

NDC Package Code 25021-305-66

The NDC Code 25021-305-66 is assigned to a package of 1 vial in 1 carton > 18 ml in 1 vial of Chlorothiazide Sodium, a human prescription drug labeled by Sagent Pharmaceuticals. The product's dosage form is injection, powder, lyophilized, for solution and is administered via intravenous form.This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package.

Field Name	Field Value
NDC Code	25021-305-66
Package Description	1 VIAL in 1 CARTON > 18 mL in 1 VIAL
Proprietary Name	Chlorothiazide Sodium What is the Proprietary Name? The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
Non-Proprietary Name	Chlorothiazide Sodium What is the Non-Proprietary Name? The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
11-Digit NDC Billing Format	25021030566 NDC Format for Billing For insurance billing purposes the Centers for Medicare & Medicaid Services (CMS) created an 11 digit NDC derivative identifier. If the NDC Package code is less than 11 digits the code must be padded with leading zeros. The leading zeros must be added to the appropriate segment to create a 5-4-2 configuration.
Billing Unit	EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Estimated Billable Units per Package	1 EA
RxNorm Crosswalk	484152 - RxCUI What is RxNorm? The RxNorm crosswalk provides a normalized naming system for generic and branded drugs by assigning unique concept identifiers (RxCUI) to each NDC.
Product Type	Human Prescription Drug What kind of product is this? Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
Labeler Name	Sagent Pharmaceuticals
Dosage Form	Injection, Powder, Lyophilized, For Solution - A dosage form intended for the solution prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections.
Administration Route(s)	Intravenous - Administration within or into a vein or veins. Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)	CHLOROTHIAZIDE SODIUM 500 mg/18mL CHLOROTHIAZIDE SODIUM 500 mg/18mL
Pharmacological Class(es)	Increased Diuresis - [PE] (Physiologic Effect) Thiazide Diuretic - [EPC] (Established Pharmacologic Class) Thiazides - [CS] Increased Diuresis - [PE] (Physiologic Effect) Thiazide Diuretic - [EPC] (Established Pharmacologic Class) Thiazides - [CS]
Sample Package	No Sample Package? This field Indicates whether this package is a sample packaging or not.
Marketing Category	ANDA - A product marketed under an approved Abbreviated New Drug Application. What is the Marketing Category? Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
FDA Application Number	ANDA202462 What is the FDA Application Number? This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Start Marketing Date	12-15-2019 What is the Start Marketing Date? This is the date that the labeler indicates was the start of its marketing of the drug product.
Listing Expiration Date	12-31-2022 What is the Listing Expiration Date? This is the date when the listing record will expire if not updated or certified by the product labeler.
Exclude Flag	N What is the NDC Exclude Flag? This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".

NDC Code Structure

25021 - Sagent Pharmaceuticals
- 25021-305 - Chlorothiazide Sodium
  - 25021-305-66 - 1 VIAL in 1 CARTON

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the disclaimer below.

NDC HCPCS Crosswalk

This crosswalk is intended to help the public understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes.

NDC 25021-305-66 HCPCS crosswalk information with package details and bill units information.

NDC Billing Code	HCPCS Code	HCPCS Code Desc.	Dosage	Package Size	Package Quantity	Billable Units	Billable Units / Pkg
25021030566	J1205	Chlorothiazide sodium inj	500 MG	1	1	1	1

* Please review the disclaimer below.

Other Product Packages

The following packages are also available for Chlorothiazide Sodium with product NDC 25021-305.

NDC Package Code	Package Description
25021-305-20	1 VIAL in 1 CARTON > 18 mL in 1 VIAL

* Please review the disclaimer below.

Previous Code: 25021-305

Next Code: 25021-308